Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide

Molecular Pharmaceutics

Volumn 12, Issue 11, 2015, Pages 3943-3952

  Kimoto, Emi ^a   Li, Rui ^a   Scialis, Renato J ^a   Lai, Yurong ^b   Varma, Manthena V S ^a  

^a PFIZER INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

gemfibrozil; gemfibrozil 1 O glucuronide; hepatic disposition; mathematical modeling; multidrug resistance associated proteins (MRPs); organic anion transporting polypeptide (OATP); sandwich cultured human hepatocytes (SCHH); sinusoidal efflux

Indexed keywords

ANION; DRUG METABOLITE; GEMFIBROZIL; GEMFIBROZIL 1 O BETA GLUCURONIDE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; POLYPEPTIDE; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER;

ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; GENE OVEREXPRESSION; GLUCURONIDATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL; MATHEMATICAL MODEL; MEMBRANE VESICLE; PRIORITY JOURNAL; HEK293 CELL LINE; LIQUID CHROMATOGRAPHY; LIVER; METABOLISM; TANDEM MASS SPECTROMETRY; THEORETICAL MODEL; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, LIQUID; GEMFIBROZIL; GLUCURONIDES; HEK293 CELLS; HEPATOCYTES; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER; MODELS, THEORETICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; TANDEM MASS SPECTROMETRY;

EID: 84946407805     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00411     Document Type: Article

References (56)

1. Yoshida, K.; Maeda, K.; Sugiyama, Y. Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms Annu. Rev. Pharmacol. Toxicol. 2013, 53, 581-612 10.1146/annurev-pharmtox-011112-140309
2. Pfeifer, N. D.; Yang, K.; Brouwer, K. L. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes J. Pharmacol. Exp. Ther. 2013, 347 (3) 727-36 10.1124/jpet.113.207472
3. Kock, K.; Brouwer, K. L. A perspective on efflux transport proteins in the liver Clin. Pharmacol. Ther. 2012, 92 (5) 599-612 10.1038/clpt.2012.79
4. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9 (3) 215-36 10.1038/nrd3028
5. Neuvonen, P. J.; Niemi, M.; Backman, J. T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clin. Pharmacol. Ther. 2006, 80 (6) 565-81 10.1016/j.clpt.2006.09.003
6. Tucker, G. T.; Houston, J. B.; Huang, S. M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus Clin. Pharmacol. Ther. 2001, 70 (2) 103-14 10.1067/mcp.2001.116891
7. Wienkers, L. C.; Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data Nat. Rev. Drug Discovery 2005, 4 (10) 825-33 10.1038/nrd1851
8. Todd, P. A.; Ward, A. Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia Drugs 1988, 36 (3) 314-39 10.2165/00003495-198836030-00004
9. Mano, Y.; Usui, T.; Kamimura, H. The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver Drug Metab. Dispos. 2007, 35 (11) 2040-4 10.1124/dmd.107.017269
10. Backman, J. T.; Kyrklund, C.; Neuvonen, M.; Neuvonen, P. J. Gemfibrozil greatly increases plasma concentrations of cerivastatin Clin. Pharmacol. Ther. 2002, 72 (6) 685-91 10.1067/mcp.2002.128469
11. Niemi, M.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide Diabetologia 2003, 46 (3) 347-51
12. Varma, M. V.; Lin, J.; Bi, Y. A.; Kimoto, E.; Rodrigues, D. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-beta-Glucuronide Drug Metab. Dispos. 2015, 43, 1108 10.1124/dmd.115.064303
13. Ogilvie, B. W.; Zhang, D.; Li, W.; Rodrigues, A. D.; Gipson, A. E.; Holsapple, J.; Toren, P.; Parkinson, A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions Drug Metab. Dispos. 2006, 34 (1) 191-7 10.1124/dmd.105.007633
14. Shitara, Y.; Hirano, M.; Sato, H.; Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil J. Pharmacol. Exp. Ther. 2004, 311 (1) 228-36 10.1124/jpet.104.068536
15. Varma, M. V.; Lai, Y.; Kimoto, E.; Goosen, T. C.; El-Kattan, A. F.; Kumar, V. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide Pharm. Res. 2013, 30 (4) 1188-99 10.1007/s11095-012-0956-5
16. Honkalammi, J.; Niemi, M.; Neuvonen, P. J.; Backman, J. T. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses Drug Metab. Dispos. 2011, 39 (10) 1977-86 10.1124/dmd.111.040931
17. Honkalammi, J.; Niemi, M.; Neuvonen, P. J.; Backman, J. T. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses Clin. Pharmacol. Ther. 2012, 91 (5) 846-55 10.1038/clpt.2011.313
18. Bi, Y. A.; Kazolias, D.; Duignan, D. B. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport Drug Metab. Dispos. 2006, 34 (9) 1658-65 10.1124/dmd.105.009118
19. Bi, Y. A.; Kimoto, E.; Sevidal, S.; Jones, H. M.; Barton, H. A.; Kempshall, S.; Whalen, K. M.; Zhang, H.; Ji, C.; Fenner, K. S.; El-Kattan, A. F.; Lai, Y. In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation Drug Metab. Dispos. 2012, 40 (6) 1085-92 10.1124/dmd.111.043489
20. Kimoto, E.; Walsky, R.; Zhang, H.; Bi, Y. A.; Whalen, K. M.; Yang, Y. S.; Linder, C.; Xiao, Y.; Iseki, K.; Fenner, K. S.; El-Kattan, A. F.; Lai, Y. Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes Drug Metab. Dispos. 2012, 40 (2) 407-11 10.1124/dmd.111.039297
21. Kimoto, E.; Yoshida, K.; Balogh, L. M.; Bi, Y. A.; Maeda, K.; El-Kattan, A.; Sugiyama, Y.; Lai, Y. Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes Mol. Pharmaceutics 2012, 9 (12) 3535-42 10.1021/mp300379q
22. Jones, H. M.; Barton, H. A.; Lai, Y.; Bi, Y. A.; Kimoto, E.; Kempshall, S.; Tate, S. C.; El-Kattan, A.; Houston, J. B.; Galetin, A.; Fenner, K. S. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data Drug Metab. Dispos. 2012, 40 (5) 1007-17 10.1124/dmd.111.042994
23. Li, R.; Ghosh, A.; Maurer, T. S.; Kimoto, E.; Barton, H. A. Physiologically based pharmacokinetic prediction of telmisartan in human Drug Metab. Dispos. 2014, 42 (10) 1646-55 10.1124/dmd.114.058461
24. Varma, M. V.; Bi, Y. A.; Kimoto, E.; Lin, J. Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model J. Pharmacol. Exp. Ther. 2014, 351 (1) 214-23 10.1124/jpet.114.215970
25. Varma, M. V.; Lai, Y.; Feng, B.; Litchfield, J.; Goosen, T. C.; Bergman, A. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions Pharm. Res. 2012, 29 (10) 2860-73 10.1007/s11095-012-0792-7
26. Kimoto, E.; Chupka, J.; Xiao, Y.; Bi, Y. A.; Duignan, D. B. Characterization of digoxin uptake in sandwich-cultured human hepatocytes Drug Metab. Dispos. 2011, 39 (1) 47-53 10.1124/dmd.110.034298
27. Kilford, P. J.; Stringer, R.; Sohal, B.; Houston, J. B.; Galetin, A. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes Drug Metab. Dispos. 2009, 37 (1) 82-9 10.1124/dmd.108.023853
28. Li, R.; Barton, H. A.; Maurer, T. S. Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations CPT: Pharmacometrics Syst. Pharmacol. 2014, 3, e151 10.1038/psp.2014.50
29. Center for Drug Evaluation and Research (CDER). Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations [Draft Guidance]. U.S. Department of Health and Human Services; U.S. Food and Drug Administration: Rockville, MD, 2012; http://www.fda.gov/downloads/Drugs/Guidance-ComplianceRegulatoryInformation/Guidances/ucm292362.pdf.
30. Committee for Human Medicinal Products (CHMP). Guideline on the Investigation of Drug Interactions [Final]. European Medicines Agency: London, 2012; http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf.
31. Hirano, M.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1 Drug Metab. Dispos. 2006, 34 (7) 1229-36 10.1124/dmd.106.009290
32. Nakagomi-Hagihara, R.; Nakai, D.; Tokui, T. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans Xenobiotica 2007, 37 (4) 416-26 10.1080/00498250601188808
33. Nakagomi-Hagihara, R.; Nakai, D.; Tokui, T.; Abe, T.; Ikeda, T. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1 Xenobiotica 2007, 37 (5) 474-86 10.1080/00498250701278442
34. Sharma, P.; Butters, C. J.; Smith, V.; Elsby, R.; Surry, D. Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins Eur. J. Pharm. Sci. 2012, 47 (1) 244-55 10.1016/j.ejps.2012.04.003
35. Sabordo, L.; Sallustio, B. C.; Evans, A. M.; Nation, R. L. Hepatic disposition of the acyl glucuronide1-O-gemfibrozil-beta-D-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation J. Pharmacol. Exp. Ther. 1999, 288 (2) 414-20
36. Sallustio, B. C.; Fairchild, B. A.; Shanahan, K.; Evans, A. M.; Nation, R. L. Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver Drug Metab. Dispos. 1996, 24 (9) 984-9
37. Hirouchi, M.; Kusuhara, H.; Onuki, R.; Ogilvie, B. W.; Parkinson, A.; Sugiyama, Y. Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4 Drug Metab. Dispos. 2009, 37 (10) 2103-11 10.1124/dmd.109.027193
38. Kusuhara, H.; Sugiyama, Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney Drug Metab. Pharmacokinet. 2009, 24 (1) 37-52 10.2133/dmpk.24.37
39. Li, R.; Barton, H. A.; Varma, M. V. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved Clin. Pharmacokinet. 2014, 53 (8) 659-78 10.1007/s40262-014-0156-z
40. Bi, Y. A.; Qiu, X.; Rotter, C. J.; Kimoto, E.; Piotrowski, M.; Varma, M. V.; Ei-Kattan, A. F.; Lai, Y. Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin Biopharm. Drug Dispos. 2013, 34 (8) 452-61 10.1002/bdd.1861
41. Li, N.; Bi, Y. A.; Duignan, D. B.; Lai, Y. Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes Mol. Pharmaceutics 2009, 6 (4) 1180-9 10.1021/mp900044x
42. Qiu, X.; Bi, Y. A.; Balogh, L. M.; Lai, Y. Absolute measurement of species differences in sodium taurocholate cotransporting polypeptide (NTCP/Ntcp) and its modulation in cultured hepatocytes J. Pharm. Sci. 2013, 102 (9) 3252-63 10.1002/jps.23582
43. Lengyel, G.; Veres, Z.; Tugyi, R.; Vereczkey, L.; Molnar, T.; Glavinas, H.; Krajcsi, P.; Jemnitz, K. Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes Hepatol. Res. 2008, 38 (3) 300-9 10.1111/j.1872-034X.2007.00255.x
44. Jemnitz, K.; Veres, Z.; Tugyi, R.; Vereczkey, L. Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes Toxicol. In Vitro 2010, 24 (2) 605-10 10.1016/j.tiv.2009.10.009
45. De Bruyn, T.; Chatterjee, S.; Fattah, S.; Keemink, J.; Nicolai, J.; Augustijns, P.; Annaert, P. Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity Expert Opin. Drug Metab. Toxicol. 2013, 9 (5) 589-616 10.1517/17425255.2013.773973
46. Vildhede, A.; Wisniewski, J. R.; Noren, A.; Karlgren, M.; Artursson, P. Comparative proteomic analysis of human liver tissue and isolated hepatocytes with a focus on proteins determining drug exposure J. Proteome Res. 2015, 14, 3305 10.1021/acs.jproteome.5b00334
47. LOPID. Label and Approval History for LOPID, NDA No. 018422 U.S. Department of Health and Human Services; U.S. Food and Drug Administration: Rockville, MD; http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label-ApprovalHistory#apphist.
48. Staffa, J. A.; Chang, J.; Green, L. Cerivastatin and reports of fatal rhabdomyolysis N. Engl. J. Med. 2002, 346 (7) 539-40 10.1056/NEJM200202143460721
49. Kock, K.; Ferslew, B. C.; Netterberg, I.; Yang, K.; Urban, T. J.; Swaan, P. W.; Stewart, P. W.; Brouwer, K. L. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4 Drug Metab. Dispos. 2014, 42 (4) 665-74 10.1124/dmd.113.054304
50. Hardwick, R. N.; Fisher, C. D.; Canet, M. J.; Scheffer, G. L.; Cherrington, N. J. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease Drug Metab. Dispos. 2011, 39 (12) 2395-402 10.1124/dmd.111.041012
51. Clarke, J. D.; Hardwick, R. N.; Lake, A. D.; Canet, M. J.; Cherrington, N. J. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression J. Pharmacol. Exp. Ther. 2014, 348 (3) 452-8 10.1124/jpet.113.211284
52. Lake, A. D.; Novak, P.; Fisher, C. D.; Jackson, J. P.; Hardwick, R. N.; Billheimer, D. D.; Klimecki, W. T.; Cherrington, N. J. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease Drug Metab. Dispos. 2011, 39 (10) 1954-60 10.1124/dmd.111.040592
53. Ferslew, B. C.; Johnston, C. K.; Tsakalozou, E.; Bridges, A. S.; Paine, M. F.; Jia, W.; Stewart, P. W.; BarrittIV, A. S.; Brouwer, K. L. Altered morphine glucuronide and bile acid disposition in patients with non-alcoholic steatohepatitis Clin. Pharmacol. Ther. 2015, 97, 419-427 10.1002/cpt.66
54. Bailey, M. J.; Dickinson, R. G. Acyl glucuronide reactivity in perspective: biological consequences Chem.-Biol. Interact. 2003, 145 (2) 117-37 10.1016/S0009-2797(03)00020-6
55. Sallustio, B. C.; Sabordo, L.; Evans, A. M.; Nation, R. L. Hepatic disposition of electrophilic acyl glucuronide conjugates Curr. Drug Metab. 2000, 1 (2) 163-80 10.2174/1389200003339153
56. Sallustio, B. C.; Harkin, L. A.; Mann, M. C.; Krivickas, S. J.; Burcham, P. C. Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase-II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycones? Toxicol. Appl. Pharmacol. 1997, 147 (2) 459-64 10.1006/taap.1997.8322